Clinical ResearchClinical TrialSafety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome: Primary Results of the DISPERSE-2 Trial
Abbreviations and Acronyms
Cited by (0)
This study was funded by AstraZeneca. In addition, Dr. Cannon receives research funding from Schering Plough, and the TIMI Study Group has received research funding from Daichi-Sankyo, Eli Lilly and Company, Bristol-Myers Squibb, and Sanofi-Aventis, manufacturers of oral antiplatelet agents.
See the Online Appendixfor a full list of investigators. See accompanying online Cardiosource Slide Set.
- 1
Dr. Husted has received research grants from AstraZeneca.
- 2
Dr. Harrington has received research grants, consultancy fees, or honoraria from AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Sanofi-Aventis, and The Medicines Company.
- 3
Dr. Emanuelsson is an employee of AstraZeneca.
- 4
Dr. Peters is a former employee of AstraZeneca.
- 5
Dr. Storey has received research grants, consultancy fees, or honoraria from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, Sanofi-Aventis, and The Medicines Company.